Intensive Induction Chemotherapy (IC) Vs Hypomethylating Agents plus Venetoclax (HMA/VEN) in IDH1-or IDH2-Mutant Newly Diagnosed Acute Myeloid Leukemia ( AML) - a Multicenter Cohort Study

被引：0

作者：

Bewersdorf, Jan Philipp ^{[1
]}

Shimony, Shai ^{[2
]}

Shallis, Rory M. ^{[3
]}

Liu, Yiwen ^{[4
]}

Schaefer, Eva Johanna ^{[5
]}

Zeidan, Amer M. ^{[6
,7
]}

Goldberg, Aaron D. ^{[1
]}

Stein, Eytan M. ^{[1
]}

Marcucci, Guido ^{[8
]}

Lindsley, R. Coleman ^{[9
]}

Chen, Evan C. ^{[5
]}

Ramos, Jorge ^{[10
]}

Stein, Anthony Selwyn ^{[11
]}

DeAngelo, Daniel J. ^{[12
]}

Neuberg, Donna S. ^{[4
]}

Stone, Richard M. ^{[12
]}

Ball, Brian J. ^{[10
]}

Stahl, Maximilian ^{[13
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Harvard Med Sch, DanaFarber Canc Inst, Dept Med Oncol, Boston, MA USA

[3] Yale Univ, Sect Hematol, Dept Internal Med, Yale Sch Med, New Haven, CT USA

[4] DanaFarber Canc Inst, Dept Data Sci, Boston, MA USA

[5] Dana Farber Canc Inst, Med Oncol, Boston, MA USA

[6] Yale Univ, Dept Internal Med, Yale Sch Med, New Haven, CT USA

[7] Yale Univ, Yale Canc Ctr, New Haven, CT USA

[8] City Hope Natl Med Ctr & Beckman Res Inst, Dept Hematol Malignancies Translat Sci, Gehr Family Ctr Leukemia Res, Duarte, CA USA

[9] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

[10] City Hope Canc Ctr, Duarte, CA USA

[11] City Hope Natl Med Ctr, Duarte, CA USA

[12] Dana Farber Canc Inst, Boston, MA USA

[13] Dana Farber Inst, Boston, MA USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-174283

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[41] Venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients with RUNX1::RUNX1T1: a retrospective propensity score matching study
Wang, Miao
Cao, Han-Yu
Tan, Kai-Wen
Qiu, Qiao-Cheng
Huang, Yuan-Hong
Ge, Shuai-shuai
Wang, Zi-Hao
Chen, Jia
Tang, Xiao-Wen
Wu, De-Pei
Xue, Sheng-Li
Li, Zheng
Dai, Hai-Ping
BLOOD CANCER JOURNAL, 2023, 13 (01)
[42] Venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients with RUNX1::RUNX1T1: a retrospective propensity score matching study
Miao Wang
Han-Yu Cao
Kai-Wen Tan
Qiao-Cheng Qiu
Yuan-Hong Huang
Shuai-shuai Ge
Zi-Hao Wang
Jia Chen
Xiao-Wen Tang
De-Pei Wu
Sheng-Li Xue
Zheng Li
Hai-Ping Dai
Blood Cancer Journal, 13
[43] Ivosidenib (IVO; AG-120) in IDH1-Mutant Newly- Diagnosed Acute Myeloid Leukemia (ND AML): Updated Results from a Phase 1 Study
DiNardo, Courtney D.
Roboz, Gail J.
Stein, Eytan M.
de Botton, Stephane
Mims, Alice S.
Prince, Gabrielle T.
Altman, Jessica K.
Arellano, Martha L.
Donnellan, Will
Erba, Harry P.
Mannis, Gabriel N.
Pollyea, Daniel A.
Stein, Anthony S.
Uy, Geoffrey L.
Watts, Justin M.
Fathi, Amir T.
Kantarjian, Hagop M.
Tallman, Martin S.
Choe, Sung
Dai, David
Fan, Bin
Wang, Hongfang
Zhang, Vickie
Yen, Katharine E.
Kapsalis, Stephanie M.
Hickman, Denice
Liu, Hua
Agresta, Samuel V.
Wu, Bin
Attar, Eyal C.
Stone, Richard M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S220 - S220
[44] Outcomes of Venetoclax-Based Regimens Compared with Hypomethylating Agents (HMA) Alone or 7+3 in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): A Single Center Retrospective Analysis
Pandey, Manu
Swaminathan, Mahesh
Griffiths, Elizabeth A.
Thompson, James E.
Przespolewski, Amanda
Thota, Swapna
Baron, Jeffrey
Cronin, Tara L.
Wang, Eunice S.
BLOOD, 2019, 134
[45] Adding venetoclax or hypomethylating agents to induction chemotherapy as first-line treatment for adults with acute myeloid leukemia: a retrospective case-cohort study
Xu, Fangfei
Zhou, Kuangguo
Gong, Duanhao
Huang, Wei
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2024, 15
[46] A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure
Ong, Faustine
Garcia-Manero, Guillermo
Montalban-Bravo, Guillermo
Alvarado, Yesid
Ohanian, Maro
Konopleva, Marina
Jabbour, Elias
Jain, Nitin
Borthakur, Gautam
DiNardo, Courtney D.
Daver, Naval
Issa, Ghayas C.
Sasaki, Koji
Chien, Kelly S.
Takahashi, Koichi
Andreeff, Michael
Muftuoglu, Muharrem
Delumpa, Ricardo
Mayor, Ejiroghene
Loiselle, Christopher
Waller, Lourdes
Banks, Glenda
Kantarjian, Hagop
Cortes, Jorge E.
Short, Nicholas
BLOOD, 2022, 140 : 6206 - 6208
[47] Comparison of venetoclax and ivosidenib/enasidenib for unfit newly diagnosed patients with acute myeloid leukemia and IDH1/2 mutation: a network meta-analysis
Wang, Lida
Song, Jiwu
Xiao, Xiangming
Li, Dianfang
Liu, Tianmeng
He, Xiaopo
JOURNAL OF CHEMOTHERAPY, 2023,
[48] Ivosidenib (IVO; AG-120) in IDH1-mutant newly-diagnosed acute myeloid leukemia (ND AML): Updated results from a phase 1 study.
Roboz, Gail J.
Dinardo, Courtney Denton
Stein, Eytan M.
de Botton, Stephane
Mims, Alice S.
Prince, Gabrielle T.
Altman, Jessica K.
Arellano, Martha Lucia
Erba, Harry Paul
Pollyea, Daniel Aaron
Stein, Anthony Selwyn
Watts, Justin M.
Fathi, Amir Tahmasb
Kantarjian, Hagop M.
Tallman, Martin S.
Fan, Bin
Liu, Hua
Wu, Bin
Attar, Eyal C.
Stone, Richard M.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[49] Comparison of venetoclax and ivosidenib/enasidenib for unfit newly diagnosed patients with acute myeloid leukemia and IDH1/2 mutation: a network meta-analysis
Wang, Lida
Song, Jiwu
Xiao, Xiangming
Li, Dianfang
Liu, Tianmeng
He, Xiaopo
JOURNAL OF CHEMOTHERAPY, 2024, 36 (03) : 202 - 207
[50] Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia
Atluri, Himachandana
Maiti, Abhishek
Sasaki, Koji
Daver, Naval
Alvarado, Yesid
Hossain, Md Feroz
Wang, Xuemei
Pemmaraju, Naveen
Takahashi, Koichi
Borthakur, Gautam
Ferrajoli, Alessandra
Short, Nicholas
Abbas, Hussein A.
Ravandi, Farhad
Jabbour, Elias
Andreeff, Michael
Garcia-Manero, Guillermo
Kantarjian, Hagop
Konopleva, Marina
DiNardo, Courtney D.
BLOOD, 2022, 140 : 6170 - 6172

← 1 2 3 4 5 →